Study Purpose:Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody
Not yet recruiting
Amyotrophic Lateral Sclerosis , Plasmapheresis
Type of Intervention:
Study Chair(s)/Principal Investigator(s):
Coordinating Center Contact Information
National Taiwan University Hospital
Estimated Study Start Date:
11 / 01 / 2022
Estimated Study Completion Date:
03 / 31 / 2025
Posting Last Modified Date:
10 / 05 / 2022
Date Study Added to neals.org:
10 / 03 / 2022
1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
2. Agree to receive plasmapheresis intervention.
3. Agree to participate in the trial and receive serial examinations and follow up.
1. Patients without plasma anti-NRIP autoantibody.
2. Patients requiring permanent ventilator support for ALS progression.
3. Not able to receive plasmapheresis or trial-related examinations.
4. Under pregnancy.
5. Blood fibrinogen level less than 50 mg/dl.
6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.